Biren Amin, an analyst from Piper Sandler, has initiated a new Buy rating on Monopar Therapeutics Inc (MNPR).
Biren Amin has given his Buy rating due to a combination of factors surrounding Monopar Therapeutics Inc. The primary driver is the potential of ALXN1840, a treatment for Wilson disease, which affects approximately 5,000 patients in the United States. The drug was acquired from AstraZeneca after they discontinued the program, despite positive Phase 3 trial results. Monopar plans to file for regulatory approval by the end of 2025 or early 2026, and there is a strong likelihood of FDA approval given the unmet medical need, especially for patients with neurological symptoms.
Biren Amin also highlights the strategic acquisition of ALXN1840 as a significant value opportunity for shareholders, as Monopar obtained the asset with minimal upfront costs. Additionally, Monopar is developing a therapy targeting uPAR for solid tumors, which presents further upside potential. The analyst projects peak sales of $274 million in the US and EU, adjusted for risk and royalties, and anticipates sustainable profitability by 2028 with a modest commercial marketing effort. These factors collectively contribute to the Buy rating for Monopar Therapeutics Inc.